PROGRESS IN NEUROBIOLOGY is a prestigious journal dedicated to advancing the field of neuroscience, published by Pergamon-Elsevier Science Ltd. With an impressive impact factor, it stands as a critical resource for researchers, professionals, and students alike, featuring rigorous peer-reviewed articles that explore the latest developments in neurobiology. The journal has established itself as a leading publication, ranked in the Q1 category for Neuroscience (miscellaneous) and holding a notable 13/113 rank in General Neuroscience per Scopus metrics, placing it in the top 12% of its field. Since its inception in 1959, PROGRESS IN NEUROBIOLOGY has covered a wide array of topics, from molecular mechanisms to cognitive processes, fostering a comprehensive understanding of brain functions. While the journal is not open access, it ensures accessibility to profound knowledge through institutional subscriptions. Researchers and scholars will find critical analyses and innovative research that are pivotal for both foundational knowledge and cutting-edge investigations in the neuroscience realm.

NEUROREPORT is a distinguished journal in the field of neuroscience, published by Lippincott Williams & Wilkins. With an ISSN of 0959-4965 and an E-ISSN of 1473-558X, the journal has established itself as a vital platform for disseminating innovative research and developments in the dynamic area of neuroscience since its inception in 1990. Currently, it is positioned in the Q3 category of the 2023 Journal Rankings, reflecting its respectable standing within the community of neuroscience professionals, ranked #74 out of 113 in general neuroscience on Scopus, placing it in the 34th percentile. While it operates on a traditional subscription model, NEUROREPORT is committed to fostering knowledge sharing in the realm of neurobiology, neuropharmacology, and cognitive studies among researchers, professionals, and students alike. With its broad scope and commitment to scientific excellence, the journal continues to be a cornerstone for those seeking to stay ahead in the evolving landscape of neurological research.

NEUROLOGICAL SCIENCES, published by SPRINGER-VERLAG ITALIA SRL, is a premier journal that has been a cornerstone in the field of neurology and related disciplines since its inception in 1996. With an impressive Q1 ranking in Dermatology and Q2 rankings in Neuroloy (clinical) as well as Psychiatry and Mental Health, this journal consistently delivers high-quality peer-reviewed research that informs and shapes clinical practice. The journal boasts a significant presence on Scopus, positioned in the 89th percentile for Dermatology, 73rd for Psychiatry and Mental Health, and 72nd for Neurology (clinical), reflecting its influential contributions to medical knowledge. Open Access options are available, ensuring that this valuable research is accessible to a wider audience committed to advancing their understanding of neurological sciences. As it converges into future years (2024 and beyond), NEUROLOGICAL SCIENCES aims to continue foster collaboration and innovation amongst researchers, professionals, and students within the neurology and mental health domains, making it an indispensable resource for those dedicated to improving patient outcomes and advancing scholarly dialogue.

Neuroscience Bulletin is a prestigious academic journal published by SPRINGER, focusing on the dynamic and interdisciplinary field of neuroscience. Established in 2005, this journal has consistently provided a platform for groundbreaking research, showcasing contributions that span various aspects of neuroscience, physiology, and medicine. With an admirable impact factor and recognition as a Q1 journal in both Medicine and Neuroscience categories for 2023, it ranks highly in the Scopus metrics, reflecting its importance in advancing scientific knowledge and practice. Researchers and professionals alike benefit from its cutting-edge articles, which are accessible through traditional subscription models. The Neuroscience Bulletin plays a crucial role in disseminating significant findings and fostering collaboration within the global research community, making it an essential resource for anyone engaged in the exploration of neural mechanisms, treatments, and innovations.

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

Purinergic Signalling, published by Springer, is a pivotal academic journal dedicated to the exploration of purinergic signaling pathways and their implications in various biological processes. Since its inception in 2004, the journal has made significant contributions to the fields of Cell Biology, Cellular and Molecular Neuroscience, and Molecular Biology, consistently ranking in the Q3 category in recent assessments. With a strong focus on the molecular mechanisms of purines and their roles in physiology and pathology, Purinergic Signalling serves as an essential resource for researchers and professionals seeking to understand the complexity of cellular communication. Although it does not offer open access, the journal ensures a broad dissemination of high-quality research findings, making it a vital tool for academic advancement in the fields of neuroscience and molecular biology. Its commitment to scholarly excellence is reflected in its Scopus rankings, where it is competitively positioned within its categories. As we approach its 20th anniversary in 2024, Purinergic Signalling continues to inspire and inform cutting-edge research in the dynamic landscape of life sciences.

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

Molecular Brain is a prestigious open-access journal published by BMC, dedicated to advancing the field of neuroscience with a particular focus on cellular and molecular mechanisms. Since its inception in 2008, the journal has been committed to disseminating high-quality research that explores the intricate workings of the brain, particularly in areas related to cellular and molecular neuroscience. Located in the heart of London, England, Molecular Brain has garnered significant recognition in the academic community, boasting a 2023 categorization in the Q2 quartile for both Cellular and Molecular Neuroscience and Molecular Biology, reflecting its growing influence and relevance in these fields. With its Scopus ranks placing it in the top 32% and 38% of its respective categories, the journal serves as an essential platform for researchers, professionals, and students alike, encouraging collaboration and knowledge-sharing through its accessible online format.

TRENDS IN NEUROSCIENCES, published by CELL PRESS, is a leading journal in the field of neuroscience, offering cutting-edge insights and important developments in the rapidly evolving landscape of brain research. With an impressive Impact Factor and ranking in the top quartile (Q1) of the category for Neuroscience (miscellaneous), it is positioned as a vital resource for researchers and professionals seeking to stay abreast of the latest discoveries and trends from 1978 to the present. Specifically ranked #3 out of 113 in General Neuroscience by Scopus, this journal promotes the interdisciplinary exchange of ideas and knowledge, making it an essential platform for students and experienced scholars alike. Although it is not an Open Access journal, its value lies in its rigorous peer-review process and commitment to maintaining the highest standards of academic integrity. By continuing to explore the complexities of neural processes and behavior, TRENDS IN NEUROSCIENCES plays a crucial role in shaping the future of neuroscience research and education.

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.